Navigation Links
New Microbial Genome-to-Array Service

The new service combines next-generation sequencing with latest microarray


HEIDELBERG, Germany, and LA JOLLA, Calif., Dec. 10 /PRNewswire/ -- Partnering with Prognosys Biosciences febit offers a new Genome-to-Array Service. This Service gives scientists access to the latest technology and know-how in sequencing and microarrays even for DNA where no standard microarrays are available. Using this service, scientists can go from biological genetic material to a working microarray experiment in weeks. Scientists in the field of microbial genomics for example now have a powerful and affordable tool for the analysis of unknown microbial DNA.

The Californian company Prognosys Biosciences contributes the sequencing of the organism's DNA by using next-generation sequencing. febit's Geniom Technology is used for preparative sample enrichment and supports the assembly process following sequencing. The data resulting from the next-generation sequencing procedure is the basis for synthesis of the biochip for microarray analysis. The biochip can be produced and analyzed in the Geniom One instrument either by the customer or as a service by febit.

In addition, febit will launch a new microarray analysis device in spring 2008, the Geniom RT Analyzer. The lower priced RT Analyzer enables customers to analyze Geniom Biochips, but does not include the ability to synthesize the chips themselves like the Geniom One product.

Anthony Caruso, Vice President Informatics & Application Software of febit inc., stated: "The powerful bioinformatics basis of the Geniom Technology enables us to offer this easy-to-use service to our customers for a very reasonable price."

About Prognosys Biosciences

Prognosys Biosciences, Inc. La Jolla (CA), is developing innovative assay technologies.

About febit

Developing innovative and creative technologies for genomic research is the corporate mission of the febit group, a German-American biotech company. Geniom is a technological and service platform successfully used in basic and applied research of renowned institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes providing superior time and cost efficiency combined with an unsurpassed spectrum of applications. With the Geniom Technology febit now enters the high-potential market of synthetic biology with a novel method for production of synthetic genes. Using both, highly integrated automation and extensive customizability, febit meets essential needs of current biomedical research.


febit holding gmbh Russo Partners, LLC

Eva Sterzel David Schull or Wendy Lau

Public Relations Manage +1-212-845-4271

+49 (6221) 6510-300

SOURCE febit
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
2. Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA Superbug
3. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
4. Change in Medicare and Medicaid Legislation Creates Market for Antimicrobial Coatings In the U.S.
5. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
6. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
7. Pharsight Expands Strategic Consulting Services Team
8. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
9. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
10. BioReliance Launches Next-Generation Genotoxicity Screening Service
11. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
Post Your Comments:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):